AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Zur Rose Group AG

Share Issue/Capital Change Jan 3, 2019

1021_rns_2019-01-03_f68b6b4c-bd6d-4239-8a91-b4dcb4593445.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

News Details

Corporate | 3 January 2019 18:00

Zur Rose Group increases share capital

EQS Group-News: Zur Rose Group AG / Key word(s): Capital Increase

03.01.2019 / 18:00


Press release

Zur Rose Group increases share capital

Zur Rose Group AG (SIX: ROSE) announces that its share capital recorded in the commercial register was increased from 8,369,985 shares by 355,887 shares to 8,725,872 shares. The new shares have been issued out of the existing authorized capital for payment of the share portion of the purchase price in connection with the acquisition of the e-commerce activities of Germany’s third-largest online pharmacy medpex, which will be consummated soon.

Investors and analyst contact

Marcel Ziwica, Chief Financial Officer

Email: [email protected], phone: +41 58 810 11 49

Media contact

Pascale Ineichen, spokesperson

Email: [email protected], phone: +41 52 724 08 18

Financial Calendar

23 January 2019 Sales 2018

21 March 2019 Annual results 2018

17 April 2019 Q1/2019 Trading Update

23 May 2019 Annual General Meeting

21 August 2019 2019 Half-Year Results

23 October 2019 Q3/2019 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe’s largest online pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management in order to increase therapy safety. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.

The Zur Rose Group is internationally present with strong brands, including Germany’s best-known pharmacy brand DocMorris. The company employs over 1,000 people at various locations and generated a turnover of CHF 983 million in the 2017 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com


End of Corporate News


Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland
Phone: +41 52 724 08 14
Internet: www.zurrosegroup.com
ISIN: CH0042615283
Listed: SIX Swiss Exchange
End of News EQS Group News Service

show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.